Title:
Associate Professor

Institute:
University Health Network

Department:
Laboratory Hematology

Province:
Ontario

Training:
Postdoctoral fellow, Molecular Cytogenetic Program, University of Toronto
PhD, Institute of Medical Science, University of Toronto
MD, Department of Medicine, Jiangxi Medical College
FRCPC in Hematological Pathology,  University of Toronto

Research interests:
Molecular cytogenetics of multiple myeloma; Identification of prognostic factors for the risk stratification of multiple myeloma

Research Projects

Project title:
Identification of novel biomarker in multiple myeloma therapy resistance

Funding period: 
2011-2013

Program:
Operating Grant (Basic Research)

Summary:
Multiple myeloma (MM) is a currently incurable B-cell tumor with survivals ranging from several months to a few years. Novel prognostic markers and new therapeutic approaches are urgently needed to improve clinical outcome. We recently identified a promising protein called MARCKS which is highly expressed in MM patients who are resistant to a novel drug called bortezomib. We plan to validate the prognostic relevance of MARCKS in a large cohort of MM patients and evaluate its role in drug resistance in MM.

CRS publications:

Chang H, Qi XY, Xu W, Patterson B. c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma. Leukemia 21:1572-74, 2007.

Chang H, Qi QY, Yeung J, Ning Y, Xu W. Chromosome 1p21 deletion is a novel prognostic factor in patients with multiple myeloma. Br J Haematol 139:51-54, 2007.

Chang H, Qi C, Jiang A, Xu W, Trieu Y, Reece D. Chromosome 1p21 loss correlates with 1q21 gains and independently predicts an adverse clinical outcome in patients with multiple myeloma undergoing autologous stem cell transplantation. Bone Marrow Transplant. 45:117-21, 2010.

Past CRS projects:

2005 Identification of novel prognostic markers for patients with multiple myeloma

2006 C-Maf expression in multiple myeloma